All Pharma News
Olverembatinib Approved for Commercialization in Macau China

Olverembatinib Approved for Commercialization in Macau China
PR NEWSWIRE
07 Jul 2024
Share Share
Ascentage Pharma Received US$100 Million Option Payment from Takeda

Ascentage Pharma Received US$100 Million Option Payment from Takeda
PR NEWSWIRE
03 Jul 2024
Share Share
Ascentage Pharma Submits Draft Registration for Proposed IPO of ADS

Ascentage Pharma Submits Draft Registration for Proposed IPO of ADS
PR NEWSWIRE
23 Jun 2024
Share Share
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
PR NEWSWIRE
20 Jun 2024
Share Share
EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL

EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL
PR NEWSWIRE
18 Jun 2024
Share Share
Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis

Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
PR NEWSWIRE
18 Jun 2024
Share Share
Takeda circles Ascentage`s Scemblix challenger for up to $1.3B

Takeda circles Ascentage`s Scemblix challenger for up to $1.3B
Zoey Becker FIERCE PHARMA
15 Jun 2024
Share Share
Takeda Signs Option With Ascentage For Olverembatinib License

Takeda Signs Option With Ascentage For Olverembatinib License
BUSINESSWIRE
14 Jun 2024
Share Share
Ascentage Signs Option With Takeda For Olverembatinib License

Ascentage Signs Option With Takeda For Olverembatinib License
PR NEWSWIRE
14 Jun 2024
Share Share
China NMPA approves Ascentage Pharma’s phase III study of olverembatinib

China NMPA approves Ascentage Pharma’s phase III study of olverembatinib
PHARMABIZ
12 Jun 2024
Share Share